Analyze the time and space complexity of your solution. Compare your solution to others and identify areas for improvement.

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

Discover the Darwin Godel Machine, the world’s first self-improving AI that evolves its coding skills autonomously. Learn how it works and see ...

So, I want to begin by just talking a little bit about Recursion's mission, which is to decode biology to radically improve lives. And unlike a traditional biotech, where learnings from a program ...

All told, Recursion is “deprioritizing” three clinical-stage programs, pausing another and winding down a single preclinical program in an undisclosed target, the company revealed in its first ...

Recursion will receive $7 million from Sanofi after advancing the fourth of 15 planned programs into lead optimization phase in less than a year, as part of a collaboration that could generate ...

Philip Bakleski (Phiality) has published a paper on GitHub about a method called 'Chain of Recursive Thoughts (CoRT),' which allows an AI to think more deeply by repeatedly asking itself questions.

Recursion's most advanced program is only in phase 1/2 testing. There's no guarantee that any of the pipeline candidates will be successful in clinical studies and win regulatory approvals.

Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since the company's management appeared on his program in May 2024.

Recursion trumpeted the results as if they were successful, but this program isn't going anywhere fast. The company still hasn't announced plans to launch a phase 3 study for REC-994, the ...